Retour à la liste des essais cliniquesBreast cancer

BGB-43395-101

Phase Ia/Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the CDK4 inhibitor BGB-43395 as monotherapy and in combination with other treatments in patients with HR+/HER2- metastatic breast cancer and other advanced solid tumors.

Ouvert à Paris depuis le : 23/05/2025
Public cible : Adult
Phase : Phase I

Description de l'essai

Evaluate the safety and tolerability of BGB-43395 as monotherapy in patients with advanced solid tumors, and in combination treatment settings in patients with HR+/HER2- breast cancer and other selected tumor types.;Determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the recommended dose(s) for expansion (RDE) of BGB-43395 as monotherapy in patients with advanced solid tumors, and in combination treatment settings in patients with HR+/HER2- breast cancer and other selected tumor types.

Url of the trial

Investigateur principal

MARIE PAULE SABLIN

Médecin

Contacter